FDA Approves Controversial “Pink Viagra”

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Flibanserin (Addyi) to treat low sexual desire in women despite concerns about the drug's limited efficacy and doubts over its clinical relevance. That the drug is being called the "pink Viagra" can be misleading as Viagra treats erectile dysfunction by improving blood flow while Flibanserin targets the brain, and must be taken daily.